Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8515MR)

This product GTTS-WQ8515MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8515MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ44MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ10401MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15091MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ12484MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ8298MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ11482MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ10671MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ13296MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW